News Releases

Vigilant Biosciences to Present at the Biotech Showcase™ 2016

FORT LAUDERDALE, Fla., Jan. 6, 2016 /PRNewswire/ -- Vigilant Biosciences, Inc. ("Vigilant"), a leading innovator and developer of solutions that aid in the early detection and intervention of cancer, today announced that Matthew Kim, Founder, Chairman and CEO of Vigilant Biosciences, Inc., will present at the Biotech Showcase™ 2016, taking place at the Parc 55 in San Francisco, CA, Jan. 11 - 13.

Vigilant Biosciences, Inc.

Mr. Kim is scheduled to speak on Wednesday, January 13, 2016, at 11:30 a.m. PST. Mr. Kim will review Vigilant Biosciences' business strategy and opportunities in regards to its commercialization of the OncAlert™ Oral Cancer System in 2016 as well as other products in the Company's pipeline.

About the OncAlert Oral Cancer System
The OncAlert Oral Cancer System is the first and only technology that detects specific protein markers associated with oral cancer to aid clinicians in the early detection and intervention of oral cancer. The OncAlert System, comprised of the OncAlert™ Oral Cancer RAPID Test and the OncAlert™ Oral Cancer LAB Test, uses a simple, oral rinse procedure that is easy to administer and non-invasive for the patient. The accurate, cost-effective tests can benefit every adult, with particular emphasis on high-risk populations (i.e., current and former tobacco users, those who consume excessive alcohol, and people with human papillomavirus, HPV-16). Vigilant Biosciences' OncAlertTM LAB Test is CE Marked. The OncAlertTM RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time. The OncAlert Oral Cancer System is not yet available for sale in the U.S.

About Oral Cancer
According to the World Health Organization, there are over 600,000 new cases of head and neck cancer and 300,000 deaths each year worldwide. In the United States, more than 54,000 individuals were diagnosed with head and neck cancers in 2014, with 13,500 deaths from the disease. Historically the death rate associated with this cancer is particularly high due to late-stage diagnosis and intervention. Currently, the vast majority of patients are detected through a visual exam and/or are symptomatic, at which point they are likely late stage. As a result, oral cancer often goes undetected to the point of metastasizing. Early diagnosis of oral cancer results in a cure rate of up to 90 percent.

About Vigilant Biosciences, Inc.
Vigilant Biosciences is a leading innovator and developer of solutions that aid clinicians in the early detection and intervention of cancer. Its point-of-care and lab-based products are simple, accurate and cost-effective, empowering healthcare practitioners with an aid in the diagnosis of oral cancer early, and improving lives through earlier intervention. Vigilant Biosciences' OncAlertTM LAB Test is CE Marked. The OncAlertTM RAPID Test is currently undergoing the CE Mark registration process and not yet available for sale in any market at this time.  For more information, visit www.vigilantbiosciences.com.

Logo - http://photos.prnewswire.com/prnh/20141210/163560LOGO

SOURCE Vigilant Biosciences, Inc.

For further information: Investor Relations Contact: Steve Silver, Rx Communications Group, LLC, 917-322-2569, [email protected], Media Relations Contact: Jennifer Moritz, Zer0 to 5ive, 917-748-4006, [email protected]